ADM Tronics Announces Aurex-3 Medical Device for Treatment of Tinnitus Approved Under European Medical Device Directive.NORTHVALE, NJ--(BW HEALTHWIRE)--Nov. 23, 1999-- Delivery of Aurex-3 in Europe to Commence During December 1999 ADM See add/drop multiplexer. (language) ADM - A picture query language, extension of Sequel2. ["An Image-Oriented Database System", Y. Takao et al, in Database Techniques for Pictorial Applications, A. Blaser ed, pp. 527-538]. Tronics Unlimited, Inc. (OTCBB-ADMT) today announced that the Aurex-3(R) Medical Device for the treatment and control of tinnitus Tinnitus Definition Tinnitus is hearing ringing, buzzing, or other sounds without an external cause. Patients may experience tinnitus in one or both ears or in the head. has been approved under the European Medical Device Directive 93/42/EEC. ADM Tronics is now authorized to apply the CE mark to its product. This is a requirement for all medical devices distributed throughout the 15 countries comprising the European Union European Union (EU), name given since the ratification (Nov., 1993) of the Treaty of European Union, or Maastricht Treaty, to the European Community . Tinnitus is the medical term for a hearing condition commonly referred to as "ringing in the ears" which ranges in severity from mild to debilitating de·bil·i·tat·ing adj. Causing a loss of strength or energy. Debilitating Weakening, or reducing the strength of. Mentioned in: Stress Reduction . It has been reported that there are more than 25 million people in Europe suffering with some degree of tinnitus. Dr. Alfonso Di Mino, President of ADM Tronics and inventor of the Aurex-3, stated, "We are very excited about this approval because it allows us to launch marketing of the Aurex-3 to tinnitus sufferers throughout Europe." ADM Tronics is a technology based developer and manufacturer of a diversified line of products categorized into three distinct market segments - therapeutic, non-invasive electronic medical devices, environmentally safe chemical products and innovative topical dermatological dermatological, dermatologic pertaining to dermatology; of or affecting the skin. products. Statements contained in this press release that are not historical facts are forward looking statements, as defined in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Such forward-looking statements are subject to risks and uncertainties, detailed in the Company's filings with the Securities and Exchange Commission, that could cause actual results to differ materially from estimated results. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion